Arrhythmias & electrophysiology

Stereotactic arrhythmia radioablation in patients with refractory ventricular tachycardia: a systematic review and meta-analysis

HeartPublished systematic review and meta-analysis

Authors' conclusion

STAR significantly reduces VT episodes and ICD shocks, offering symptomatic relief. However, high recurrence rates and severe AEs underscore the need for protocol optimisation and multidisciplinary collaboration to improve STAR’s safety and efficacy in VT management.

Study context

Population
Patients with therapy-refractory monomorphic ventricular tachycardia treated with stereotactic arrhythmia radioablation (STAR)
Participants
215 patients22 studies
Outcome
Overall survival
Follow-up
Mean 11.9±6.6 months
Methodological detailsrandom-effects models with double arcsine transformation, prospective and retrospective studies only
  • Random-effects models with double arcsine transformation
  • Prospective and retrospective studies only

Pooled result

As reported in the abstract

Overall survival

69.6%

95% CI 62.6% to 76.2%

Further pooled results

Reduction in ventricular tachycardia (VT) episodes and implantable cardioverter-defibrillator (ICD) shocks/month

VT episodes reduced by
81.5% (95% CI 64.2% to 94.8%)
ICD shocks/month reduced by
84.7% (95% CI 65.1% to 98.1%)

Freedom from VT · end of follow-up

VT-free
23.1% (95% CI 10.7% to 37.7%)

Subgroup analyses by study design and planning target volume (PTV)

No significant differences in clinical outcomes between prospective and retrospective studies, nor between studies with high PTV and low PTV

Safety

Adverse events

Adverse events (AEs) reported
352
Patients with AEs reported
280
Mean AE per patient
1.26
AEs classified as severe
50.6%
AEs likely STAR-related
9.7%
  • AEs were qualitatively analysed and classified by organ system, severity and causality

Original publication

Stereotactic arrhythmia radioablation in patients with refractory ventricular tachycardia: a systematic review and meta-analysis. Heart. Published 9 July 2025. doi:10.1136/heartjnl-2025-325805

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.